FinscoFinsco

Aclaris Therapeutics (US.ACRS)

Capital Allocation Audit · Period: 2013 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ACRS · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion100.0%→
ROE-33.2%↓
Cash Conversion-→
D/E Ratio0.00↓
Gross Margin10.6%↑
US.ACRS (Aclaris Therapeutics) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   100.0%    →
ROE              -33.2%    ↓
Cash Conversion       -    →
D/E Ratio          0.00    ↓
Gross Margin      10.6%    ↑
Key Metrics
US.ACRS (Aclaris Therapeutics) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 100.0% →
ROE -33.2% ↓
Cash Conversion - →
D/E Ratio 0.00 ↓
Gross Margin 10.6% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies